Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Google Secures Pentagon AI Deal for Classified Projects 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
REGULATED INFORMATION
GHENT, Belgium, Feb. 23, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 7,521 common shares have been issued by the Company in exchange for €34,726.41 as the result of the exercise of warrants.
As a result of this transaction, Ablynx now has 55,108,065 shares outstanding.
The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,496,511 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
pdf format of the press release http://hugin.info/137912/R/1988248/729962.pdf
HUG#1988248
